Related Experiment Video

Updated: Aug 14, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

The differential engagement of arrestin surface charges by the various functional forms of the receptor

Susan M Hanson1, Vsevolod V Gurevich

  • 1Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, USA.

The Journal of Biological Chemistry
|December 13, 2005
PubMed

Insights

Arrestin proteins bind various receptor forms, with specific surface charges and domains crucial for interaction. This study reveals unique arrestin residue requirements for each receptor state, impacting signaling termination.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Signaling

Background:

  • G-protein-coupled receptor (GPCR) signaling is a critical cellular process.
  • Arrestin proteins terminate GPCR signaling by binding to activated, phosphorylated receptors.
  • Arrestins also interact with non-preferred receptor forms, influencing cellular functions.

Purpose of the Study:

  • To extensively analyze the receptor-binding surface of arrestin.
  • To understand how arrestin interacts with different functional forms of GPCRs.
  • To elucidate the role of specific arrestin residues and domains in receptor binding.

Main Methods:

  • Site-directed mutagenesis of arrestin.
  • Analysis of arrestin-receptor interactions.
  • Biochemical and biophysical characterization of arrestin mutants.

Main Results:

  • A large number of surface charges on arrestin are critical for binding all receptor forms.
  • Different functional receptor forms engage unique subsets of arrestin residues.
  • The arrestin N-domain contains additional phosphate-binding elements.
  • Active receptors preferentially bind the arrestin C-domain.
  • The interdomain contact surface is vital for binding non-preferred receptor forms.

Conclusions:

  • Arrestin-GPCR interactions are complex, involving differential engagement of arrestin surfaces by various receptor states.
  • Specific arrestin residues and domains dictate binding affinity and specificity.
  • Understanding these interactions is key to modulating GPCR signaling pathways.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

High-resolution Spatiotemporal Analysis of Receptor Dynamics by Single-molecule Fluorescence Microscopy15:13

High-resolution Spatiotemporal Analysis of Receptor Dynamics by Single-molecule Fluorescence Microscopy

Published on: July 25, 2014

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...